Investment
Features
FeesSafety
Academy
More
Pluang+

Compare T Rowe Price Group Inc (TROW) vs 22nd Century Group Inc (XXII) Price & Performance

T Rowe Price Group IncTrade
22nd Century Group IncTrade

Price performance (Past 24H)

Key statistics

T Rowe Price Group Inc vs 22nd Century Group Inc — how do they compare? T Rowe Price Group Inc trades at $105.26 (market cap $22.23B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: T Rowe Price Group Inc is far larger — about 35758.5× 22nd Century Group Inc's market cap, and T Rowe Price Group Inc pays a 4.99% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold T Rowe Price Group Inc for 115 Days and 22nd Century Group Inc for 32 Days on average.

TROWXXII
Market Cap
$22.23B$621.67K
Volume
2,834,94945,625
Sector
FinancialsConsumer Staples
52-Week High
$121.68$483.00
52-Week Low
$86.19$0.80
Typical Hold Time
115 Days32 Days
Enterprise Value
$19.43B-$3.69M
Dividend Yield
4.99%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

T Rowe Price Group Inc

T. Rowe Price (TROW) trades at $105.47, up 1.35% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 10.46, net income margin of 29.26%, and consistent dividend growth spanning 40 years. Recent earnings beat expectations in Q1 and Q2 2026, while AUM reached $1.90 trillion in August 2026 despite net outflows.

The stock presents value characteristics with attractive valuation multiples and dividend yield near 5%, though technical weakness and analyst caution (63% hold rating) suggest near-term consolidation. Key catalysts include Q3 earnings due soon and the company's expansion into ETF offerings through F/m Investments acquisition, while risks include market-sensitive revenue and competitive pressures.

22nd Century Group Inc

22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.

While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TROW

No sentiment data available yet.

XXII
100% Buy0% Sell
Avg holding period · 32 Days

About T Rowe Price Group Inc

T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.

Read more on TROW →

About 22nd Century Group Inc

22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.

Read more on XXII →